Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18  years or more: A randomised, double-blinded, active-controlled phase 1 trial

In conclusion, SYS6006.32 showed good safety profile and superior immunogenicity to the monovalent vaccine SYS6006.PMID:38461050 | DOI:10.1016/j.vaccine.2024.03.005

Source: Vaccine - March 9, 2024 Category: Allergy & Immunology Authors: Yu-Wen Su Yuan-Zheng Qiu Yuan-Hui Wang Yan Xu Chao-Chao Huang Qing Zhang Chang Su Jun-Heng Ma Wen Liu Yan Liu Mao-Sheng Zhao Han-Yu Yang Chun-Lei Li Xiang Lu Source Type: research